The 2018 Global Market for Transthyretin Amyloidosis (ATTR): Overview & Outlook (2016-2027) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Transthyretin
Amyloidosis (ATTR) – Global Market Insights, Epidemiology and Forecast
to 2027”
drug pipelines has been added to ResearchAndMarkets.com’s


According to the report, total prevalent population of ATTR in the 7
major markets ranges from approximately 19,197 cases in 2016, growing
during the study period [2016-2027].

The report also estimates higher prevalence of ATTR in the Italy with
2,044 cases in 2016 followed by France. On the other hand, United
Kingdom has the lowest prevalent population in 2016.

The report estimates that the diagnosed prevalent population of ATTR
will significantly increase during the study period [2016-2027].

Hereditary transthyretin amyloidosis (hATTR) cases are segmented in to
two segments which includes Familial Amyloid Polyneuropathy (FAP) and
Familial Amyloid Cardiomyopathy (FAC) cases. In 2016, there were 5,201
cases of Familial Amyloid Polyneuropathy and of Familial Amyloid
Cardiomyopathy in the 7MM.

Market Outlook

FDA has approved few drugs such as Vyndaqel (Pfizer Inc), Onpattro
(Alnylam Pharmaceuticals), Tegsedi (Ionis Pharmaceuticals /Akcea
Therapeutics) which are used for the treatment of Transthyretin
Amyloidosis (ATTR).

Key players such as Corino Therapeutics are involved in developing
therapies for Transthyretin Amyloidosis (ATTR).

Expected launch of emerging therapies such as CRX-1008: Corino
Therapeutics therapies will significantly impact the Transthyretin
Amyloidosis (ATTR) market during the study period (2016-2027).

Study Coverage

This report delivers an in-depth understanding of the disease,
historical & forecasted epidemiology as well as the market trends of
Transthyretin Amyloidosis (ATTR) in the United States, EU5 (Germany,
Spain, Italy, France and United Kingdom) and Japan.

The report provides the current treatment practices, emerging drugs,
market share of the individual therapies, current and forecasted market
size of Transthyretin Amyloidosis (ATTR) from 2016 to 2027 segmented by
seven major markets.

The report also covers current treatment practice/algorithm, market
drivers, market barriers and unmet medical needs to curate best of the
opportunities and assess underlying potential of the market.

Companies Featured

  • Alnylam Pharmaceuticals
  • Corino Therapeutics
  • Ionis Pharmaceuticals/Akcea Therapeutics
  • Pfizer Inc.

Key Topics Covered

1. Key Insights

2. Transthyretin Amyloidosis (ATTR): Overview at a Glance

3. Transthyretin-Related Amyloidosis: Disease Background and Overview

4. Epidemiology and Patient Population

5. Epidemiology by Country

6. 7MM Diagnosed Prevalent and Surgery Cases of ATTR Related Carpal
Tunnel Syndrome

7. Current Treatment and Medical Practices

8. Unmet Needs

9. Marketed Drugs

10. Emerging Therapies

11. Transthyretin Amyloidosis: Market Analysis

12. Transthyretin Amyloidosis: 7 Major Market Outlook

13. Market Outlook by Country

14. Market Drivers

15. Market Barriers

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/dhjmv7/the_2018_global?w=4


Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Central
Nervous System Drugs
, Endocrine
and Metabolic Disorders Drugs


I have been involved with publishing and marketing for the past 32 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.com for scheduling information.